ERBB2 and ovarian cancer: Trastuzumab labeled with α-particle emitting, 225Ac administered by intraperitoneal (i.p.)injection was effective for RIT of HER2-positive SK-OV-3 human ovarian cancer tumours in athymic mice (Borchardt et al. 2003).